Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study

Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate

“…In addition, we confirmed previous results on prothrombotic effects of third-generation progestogen-containing OC (DSG, GTD) [2]. The observations were not the result of differences between women rather than between OC, as proved by the results in women who switched OC.…”

“…Thrombin generation-based activated protein C (APC) sensitivity is a global test for the net prothrombotic effect and predicts the risk of venous thrombosis [2,3].…”

“…Normalized APC sensitivity ratios (nAPCsr) were determined by quantifying the effect of APC on thrombin generation (ETP-based APC-resistance test) as described previously [2]. The APC-resistance test was performed in duplicate and without knowledge of the OC used or any other participant's characteristics.…”

“…Thalidomide has been employed in recent years for its antiinflammatory and antiangiogenic properties in the treatment of several conditions including leprosy, systemic lupus erythematosus (SLE), Behcet's disease (BD) and solid and hematological malignancies [1,2]. An increased incidence of deep venous thrombosis (DVT) has been observed in malignancies, especially in multiple myeloma, during treatment with thalidomide combined with chemotherapy.…”

20. Planejamento familiar e anticoncepção

“…Além da dosagem do estrógeno, o risco de trombose do AHCO está associado ao tipo de progestágeno. Essa diferença no risco tornou-se evidente pelos estudos observacionais e posteriormente foi documentada pela diferença nos resultados do teste da sensibilidade à proteína C ativada, mais pronunciada em usuárias de progestágeno de terceira geração 24,25 .…”